Diagnostic yield and limitations of whole-genome sequencing for hereditary cerebellar ataxia
Less than half of the individuals with hereditary cerebellar ataxia receives a genetic diagnosis. Repeat expansions account for disproportionate number of hereditary cerebellar ataxia and have genetically heterogeneous causes. These genetic loci include <i>ATXN1</i>, <i>ATXN2</i>, <i>ATXN3</i>, <i>CACNA1A</i>, <i>ATXN7</i>, <i>ATXN8OS</i>, <i>ATXN10</i>, <i>PPP2R2B, TBP</i>, <i>ATN1</i>, <i>FMR1, BEAN1, NOP56, GLS, THAP11, GAA-FGF14, ZFHX3, FXN</i> and <i>RFC1.</i> This study aims to assess the yield of short-read whole genome sequencing in the molecular diagnosis of hereditary cerebellar ataxia. We recruited 380 patients (351 probands) from a national ataxia centre in United Kingdom. They underwent short-read whole genome sequencing as a part of the 100 000 Genomes Project. Bioinformatic pipeline of whole genome sequencing include variant prioritization in selected virtual gene panels, customized analysis with a focus on repeat expansions, structural variants and recently reported hereditary cerebellar ataxia genes. All potential genetic variants were reviewed in a multidisciplinary team, and further confirmation tests were performed as appropriate. Whole genome sequencing identified causative variants in 115 (33%) out of 351 probands. We established 46 distinct presumptive molecular diagnoses with the most frequent being <i>SPG7</i> (<i>n</i> = 22)<i>, RFC1</i> (<i>n</i> = 20) and <i>CACNA1A</i> (<i>n</i> = 10). However, it failed to detect any probands with novel ataxia gene <i>GAA-FGF14</i>, which was subsequently identified on polymerase chain reaction screening in 10 unsolved probands. In conclusion, whole genome sequencing is a useful diagnostic test in hereditary cerebellar ataxia patients and can be used to detect repeat expansions, structural and mitochondrial variants. However, identification of complex structural variants and sizing of large repeat expansions remains a challenge and require alternative molecular testing techniques.
Authors
- Bernard Brais (ORCID: https://orcid.org/0000-0003-1394-3561)
- Stephan Züchner (ORCID: https://orcid.org/0000-0002-8498-5235)
- Matt C. Danzi (ORCID: https://orcid.org/0000-0003-1568-5965)
- David Pellerin (ORCID: https://orcid.org/0000-0002-5807-995X)
- Roisin Sullivan (ORCID: https://orcid.org/0000-0002-4636-8033)
- Michael Parkinson (ORCID: https://orcid.org/0000-0002-8278-0877)
- Jana Vandrovcová (ORCID: https://orcid.org/0000-0001-9508-0477)
- Paola Giunti (ORCID: https://orcid.org/0000-0003-3508-4788)
- Nicholas William Wood (ORCID: https://orcid.org/0000-0002-9500-3348)
- Henry Houlden (ORCID: https://orcid.org/0000-0002-2866-7777)
- Wai Yan Yau (ORCID: https://orcid.org/0000-0001-6284-9163)
- Marie‐Josée Dicaire
- Emer O’Connor
Institutions
- Montreal Neurological Institute and Hospital (CA)
- University College London Hospitals NHS Foundation Trust (GB)
- University of Miami (US)
- The University of Western Australia (AU)
- Dr. John T. Macdonald Foundation (US)
- Perron Institute for Neurological and Translational Science (AU)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- McGill University (CA)
Publication Details
- Journal
- Brain Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/braincomms/fcaf188
- Citations
- 3
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.73
Funders
- Royal Australasian College of Physicians
- Department of Health, Government of Western Australia
- Canadian Institutes of Health Research